NCT07124572

Brief Summary

This study aims to develop the deep learning-based system that integrates multimodal information to automatically diagnose, stage, and grade thyroid-associated ophthalmopathy (TAO), assist in treatment decision-making, and predict patient prognosis, thereby providing novel tools to support clinical management.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
66mo left

Started Oct 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress40%
Oct 2022Oct 2031

Study Start

First participant enrolled

October 1, 2022

Completed
2.8 years until next milestone

First Submitted

Initial submission to the registry

August 6, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

August 15, 2025

Completed
5.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2030

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2031

Last Updated

August 15, 2025

Status Verified

July 1, 2025

Enrollment Period

8 years

First QC Date

August 6, 2025

Last Update Submit

August 13, 2025

Conditions

Outcome Measures

Primary Outcomes (6)

  • eye morphological parameters

    Margin reflex distances(mm)

    through study completion, average of 5 years

  • Blinking feature of patients with thyroid-associated ophthalmopathy

    Blinking frequency

    through study completion, average of 5 years

  • Ocular movement measurement

    Ocular movement ability in nine gaze positions

    through study completion, average of 5 years

  • Automatic orbital structures segmentation and measurement using deep learning methods

    Automatic segmentation and measurement of orbital structures,such as eyeball, extraocular muscle, orbital fat, bony orbital region, optic nerves, etc

    through study completion, average of 5 years

  • Automatic diagnosis, grading, staging and prediction of patients with thyroid-associated ophthalmopathy

    Patients with thyroid-associated ophthalmopathy(TAO) are classified as TAO or non-TAO. Grading is classified as mild, moderate, severe and sight-threatening. Staging is classified as active and stable.

    through study completion, average of 5 years

  • three-dimensional eye parameters

    eyelid volume

    through study completion, average of 5 years

Study Arms (2)

Participants without Thyroid-associated ophthalmopathy

Participants without thyroid-associated ophthalmopathy based on Bartley criteria.

Other: Imaging and ocular examinations

Patients with Thyroid-associated ophthalmopathy

Patients diagnosed as thyroid-associated ophthalmopathy based on Bartley criteria.

Other: Imaging and ocular examinations

Interventions

2D and 3D Facial photography, blinking videos, orbital CT and MRI images, fundus images and images of nine gaze positions are taken. Clinical information is recorded. Quality of life is assessed. Ocular examinations, such as visual acuity, levator function, exophthalmos measurement, strabismus test, visual field examination, axial length measurement, OCT, OCTA are made.

Participants without Thyroid-associated ophthalmopathyPatients with Thyroid-associated ophthalmopathy

Eligibility Criteria

Age7 Years - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

500 patients with thyroid-associated ophthalomopahty 500 patients without thyroid-associated ophthalomopahty

You may qualify if:

  • normal participants without eyelid disorders (control group)
  • patients with thyroid-associated ophthalmopathy (TAO group)
  • cooperative participants

You may not qualify if:

  • participants with pupil or cornea disorders
  • participants with history of eye injury

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Juan Ye

Hangzhou, Zhejiang, 310000, China

RECRUITING

MeSH Terms

Conditions

Graves Ophthalmopathy

Interventions

X-Rays

Condition Hierarchy (Ancestors)

Eye Diseases, HereditaryEye DiseasesGraves DiseaseExophthalmosOrbital DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesGoiterThyroid DiseasesEndocrine System DiseasesHyperthyroidismAutoimmune DiseasesImmune System Diseases

Intervention Hierarchy (Ancestors)

Electromagnetic RadiationElectromagnetic PhenomenaMagnetic PhenomenaPhysical PhenomenaRadiationRadiation, Ionizing

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 6, 2025

First Posted

August 15, 2025

Study Start

October 1, 2022

Primary Completion (Estimated)

October 1, 2030

Study Completion (Estimated)

October 1, 2031

Last Updated

August 15, 2025

Record last verified: 2025-07

Locations